| abstract |
The present invention concerns an enantiomer R of a compound of Formula (I), wherein X is -NH-R 1 or of Formula (V) or (VI), R 1 is -(CH 2 ) n -R 2 , R 2 is a linear, branched or cyclic C 1 C 6 aliphatic group, -O-(CH 2 ) n -CH 3, -NH-CO- (CH 2 ) n -CH 3, a 5- or 6-membered aliphatic or aromatic ring optionally comprising a heteroatom, a 5- or 6-membered aromatic ring substituted by one or two substituents, said substituents being selected from the group consisting of -OH, - O(alkyl C 1 C 3 ) and -OCO(alkyl C 1 C 3 ), or of Formula (V), R 3 is H or a C 1 -C 3 aliphatic group and R 4 is a linear C 1 -C 3 or a branched C 3 -C 12 aliphatic group, or R 3 is a C 1 -C 3 aliphatic group and R 4 is a linear C 1 -C 12 aliphatic group, Y is O, CH-(CH 2 ) n -CH 3 or N(CO)(CH 2 ) n -CH 3, and n is an integer from O to 6. It has been found that the enantiomers of the invention are able to release (R)- alpha-lipoic acid, ensuring a longer permanence in the body for the pharmacologically active principle than that obtainable by its direct administration, or to simulate the pharmacological action of alpha-lipoic acid itself, while exhibiting a much more intense and lasting activity. |